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Background
An HIV-1 vaccine remains elusive, in part because var-
ious factors limit the quantity and quality of the antibo-
dies raised against the viral envelope glycoprotein
complex (Env). We hypothesized that targeting Env
vaccines directly to B cells, by fusing them to molecules
that bind and activate these cells, would improve Env-
specific antibody responses.
Methods
We fused trimeric Env gp140 to A PRoliferation-Indu-
cing Ligand (APRIL), B-cell Activating Factor (BAFF),
and CD40 Ligand (CD40L).
Results
The Env-APRIL, Env-BAFF and Env-CD40L gp140 tri-
mers all enhanced the expression of activation-induced
cytidine deaminase (AID) expression, the enzyme respon-
sible for inducing somatic hypermutation, antibody affi-
nity maturation and antibody class-switching. They also
triggered IgM, IgG and IgA secretion from human B cells
in vitro. The Env-APRIL trimers induced higher anti-Env
antibody responses in rabbits, including neutralizing anti-
bodies against Tier 1 viruses. The enhanced Env-specific
responses were not associated with a general increase in
total plasma antibody concentrations, indicating that the
effect of APRIL was Env-specific. All the rabbit sera
raised against gp140 trimers, irrespective of the presence
of CD40L, BAFF or APRIL, recognized trimeric Env effi-
ciently, while sera raised against gp120 monomers did
not. The levels of trimer-binding and virus-neutralizing
antibodies were strongly correlated, suggesting that gp140
trimers are superior immunogens to gp120 monomers.
Conclusion
Targeting and activating B cells with a trimeric HIV-1
Env-APRIL fusion protein may improve the induction of
humoral immunity against HIV-1. Targeting B cells
directly may also be useful for other vaccines.
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